On Thursday, President Biden called on Congress to address lower prescription drug prices as a component of his Build Back Better initiative. His remarks did not mention the role of PBMs in drug prices. NCPA CEO Douglas Hoey urged the president to revamp the plan to include PBMs. “Bringing down drug costs requires changing the prescription payment system,” Hoey said in a statement. “Unfortunately, the president’s plan doesn’t accomplish that. The U.S. pays the highest drug costs in the world, and it is the only country with a government that supports PBMs controlling the nation’s prescription drug benefit." Read Hoey’s full statement here.
NCPA
